You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
|
|---|---|
| Published in |
Arthritis Research & Therapy, October 2017
|
| DOI | 10.1186/s13075-017-1445-3 |
| Pubmed ID | |
| Authors |
Vasco C. Romão, Edward M. Vital, João Eurico Fonseca, Maya H. Buch |
| Abstract |
Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of research. In addition to clinical phenotyping, cellular and molecular characterisation of synovial tissue and blood in patients with RA, using different technologies, can facilitate predictive testing. This narrative review will summarise the literature for the available bDMARD classes and focus on where progress has been made. We will also look ahead and consider the increasing use of 'omics' technologies, the potential they hold as well as the challenges, and what is needed in the future to fully realise our ambition of personalised bDMARD treatment. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Singapore | 1 | 25% |
| Spain | 1 | 25% |
| United Arab Emirates | 1 | 25% |
| Portugal | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 71 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 15% |
| Researcher | 11 | 15% |
| Other | 5 | 7% |
| Student > Master | 5 | 7% |
| Student > Bachelor | 4 | 6% |
| Other | 16 | 23% |
| Unknown | 19 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 27% |
| Biochemistry, Genetics and Molecular Biology | 9 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 11% |
| Immunology and Microbiology | 5 | 7% |
| Agricultural and Biological Sciences | 4 | 6% |
| Other | 8 | 11% |
| Unknown | 18 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 72. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2021.
All research outputs
#597,741
of 25,461,852 outputs
Outputs from Arthritis Research & Therapy
#43
of 3,388 outputs
Outputs of similar age
#12,744
of 338,498 outputs
Outputs of similar age from Arthritis Research & Therapy
#1
of 60 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,388 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,498 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.